Meet Our Senior Advisors

Mark Diamond

 

Mark Diamond is a senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than thirty years within the pharmaceutical and biotechnology industries.

Currently, Mark serves as the non-executive Chair of ASX listed Dimerix Limited (ASX:DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets. His extensive tenure as Managing Director and CEO at Antisense Therapeutics Limited (now Percheron Therapeutics ASX:PER) until May 2023, where he was the longest-serving CEO of a publicly traded Healthcare Company on the ASX, demonstrates his exceptional leadership and expertise.

Throughout his career, Mark has demonstrated skill in capital market engagement, capital raising, pipeline development, product out-licensing, and clinical trial conduct. His contributions were recognised by The Biotech Daily CEO of the Year award in 2022.

Prior to his roles at Dimerix and Antisense, Mark held senior product and business development positions at Faulding Pharmaceuticals (now Pfizer), where he played a key role in the company’s US, European, and international pharmaceutical operations.

Mark holds a Bachelor of Science degree from Monash University and an MBA from Macquarie University.